HPV vaccine efficacy and perspectives - Part A: HPV vaccine efficacy against invasive cancer
Monday, December 3, 2018
Main Scientific Session
•
MSS 01a
•
8:15 AM
>
8:45 AM
•
HPV vaccine efficacy and perspectives - Part A: HPV vaccine efficacy against invasive cancer
•
Auditorium I
HPV vaccines have been in use in populations for 13 years, with follow up of trial participants ahead of these cohorts. There is strong evidence of vaccine effectiveness against HPV infections and pre-cancerous lesions and it is timely to consider how soon population evidence of vaccine impact against cancer outcomes will emerge. This is particularly relevant as the WHO start to gather the evidence and develop a strategy to support a global campaign for elimination of cervical cancer as a public health problem. In this session we will hear from countries who started follow-up programs early on and also review the global situation.
8:15 AM
•
MSS 01a-01
•
Vaccine efficacy against invasive cancer: Finland
>
M.
Matti
LEHTINEN
8:30 AM
•
MSS 01a-02
•
Vaccine efficacy against invasive cancer: Scandinavia
>
M.
Mari
NYGÅRD
|